Peptide News Digest

Peptide Vaccine Extends AML Survival, Maryland Caps Ozempic Payments, Finland Curbs Chat-Based GLP-1 Prescribing

SELLAS's peptide vaccine extends leukemia survival, Maryland caps what public plans pay for Ozempic, and Finland warns off chat-based GLP-1 prescribing.

12 stories · Covering clinical-trials, research, industry, regulatory

Editor's Note

The biggest peptide result of the day had nothing to do with weight. SELLAS said its WT1 peptide vaccine, galinpepimut-S, extended median survival to 24 months from 14.7 in people with acute myeloid leukemia in remission, though the trial was open-label and the full data are still to come. Priavoid's oral D-peptide for Alzheimer's missed its main goal at 48 weeks, and a Kyoto University team showed a peptide that pushes whole antibodies into cells. Governments kept working on who pays for GLP-1s and who prescribes them. Maryland became the first state to set a payment ceiling on Ozempic for public employee plans, a council in South Korea proposed paying residents' obesity drug bills, and Finland's new guidelines tell doctors not to prescribe obesity drugs through quick chat consultations. The gray market showed up in two local TV stories: a Georgia woman who doubled her dose of mail-order retatrutide, and a South Carolina woman who developed dark spots after ordering melanotan and other peptides online.

SELLAS's Peptide Vaccine Galinpepimut-S Cut the Risk of Death 41% in Phase 3 REGAL Trial in Acute Myeloid Leukemia

In 126 people with acute myeloid leukemia in second or later remission, or in remission but unable to have a stem cell transplant, the off-the-shelf vaccine made of four WT1-derived peptides was linked to median overall survival of 24 months, versus 14.7 months on investigators' choice of best available treatment, BioSpace reported. The open-label trial met its primary endpoint, and SELLAS said it will discuss a possible accelerated path to approval with the FDA. The vaccine was invented at Memorial Sloan Kettering, which has a financial interest in SELLAS.

Priavoid's Oral D-Peptide PRI-002 Missed Its Main Alzheimer's Goal at 48 Weeks in the 304-Patient PRImus-AD Trial

In people aged 55 to 80 with mild cognitive impairment or mild dementia due to Alzheimer's, daily PRI-002 at 300 mg or 600 mg did not beat placebo on the CDR-SB scale at week 48, Priavoid said at the CTAD conference in Boston on November 17. The company pointed to trends at week 72, such as 26.7% slower decline on ADAS-Cog13 (p=0.102), but most were not statistically significant. The drug met its safety endpoint. Brain swelling (ARIA-E) occurred in 2% or fewer patients in each group, and small brain bleeds (ARIA-H) in 8% and 11.7% on the two doses versus 5% on placebo, though a safety board stopped close central MRI checks for ARIA after the first 90 patients reached 24 weeks.

Kyoto University Team Uses a Membrane-Permeabilizing Peptide to Push Whole Antibodies Into Cells in Rapid Bursts

Researchers at Kyoto University and other Japanese institutions combined tagged IgG antibodies with a three-armed version of the membrane-active peptide L17E to form microcondensates that released antibodies into cells in rapid bursts, even with salt and serum present, they reported in Nature Communications on November 16. An antibody delivered this way against TDP-43, a protein linked to ALS, kept it from gathering in stress granules. The experiments were in cells; the authors call serum stability a prerequisite for later use in living animals.

MiniMed Starts Shipping MiniMed Flex, Its Smallest Automated Insulin Pump, Across Europe

MiniMed Flex is about half the size of earlier MiniMed pumps, holds 300 units of insulin, has no screen, and is run from a phone app using the same SmartGuard algorithm as the 780G, The Diabetes Times reported. It is CE marked for people aged 2 and older with insulin-treated diabetes, including during pregnancy. It launches with the Simplera Sync sensor, with Abbott's 15-day Instinct sensor planned for Europe in 2027, and no UK date has been set.

FOX Carolina: Greenville Woman Reports Dark Skin Spots After Ordering Melanotan, Retatrutide, and NAD+ Online

Ashley Sams told FOX Carolina she noticed dark spots on her neck, back, stomach, and legs after buying melanotan, the investigational weight-loss drug retatrutide, and NAD+ online, and that one product left her short of breath. Her doctor, Nita Bijoor, told her to stop all of them and see a dermatologist, noting that many such products are labeled for research use only. None of the products is FDA-approved, and none is among the six peptides covered by HHS's new compounding policy.

Maryland Becomes the First State to Limit What Government Health Plans Pay for Ozempic and Jardiance

Maryland's Prescription Drug Affordability Board set upper payment limits on Ozempic and Jardiance for state and local government health plans, starting January 1, 2027, WYPR reported. Board staff estimate savings of about $6.1 million, and the step could let the board set limits for private insurance in 2028. Aimed Alliance warned the limits could change formularies and access, and the board said it would revise the policy if access suffers. Colorado's limit on Enbrel is blocked by a court order.

WSB-TV: Georgia Poison Center GLP-1 Calls Climbed From 38 in 2021 to 655 So Far in 2026

About 15% of callers need emergency room evaluation, and about one in five GLP-1 calls over the past two years involved unapproved gray-market drugs, Georgia Poison Center director Gaylord Lopez told WSB-TV. People confuse milligrams with milliliters and use insulin syringes, he said. Hayley Lithwick described paying about $200 online for powdered retatrutide labeled "not for human use" after losing Zepbound coverage, then taking about twice the intended dose.

Yle: Finland's New Obesity Guidelines Warn Doctors Off Chat-Based GLP-1 Prescribing and Lower the Bar for Surgery

The Finnish Medical Society Duodecim's updated Current Care Guidelines advise against prescribing obesity drugs through quick chat consultations and name semaglutide and tirzepatide as the drugs with the strongest evidence, Yle reported. Bariatric surgery can be considered at a BMI of 35 instead of 40, or 30 to 35 with poorly controlled type 2 diabetes, after about six months of basic treatment and without a required 5% pre-referral weight loss. Kela says more than 100,000 Finns used obesity medication last year.

Penn Trial: Semaglutide Eased Loss-of-Control Eating and Body Dissatisfaction Over 60 Weeks Compared With Placebo

In 120 adults seeking obesity treatment, randomized 3:2 to semaglutide 2.4 mg or placebo with lifestyle counseling, semaglutide brought larger drops in loss of control over eating, eating disorder symptoms, and body dissatisfaction, researchers reported in the International Journal of Eating Disorders. Binge frequency did not differ overall, but people with baseline binge eating were more likely to stop on semaglutide. New eating problems were rare in both groups. Novo Nordisk partly funded the study.

Korean Council Members Propose the First Local Subsidy for Wegovy and Mounjaro, Costing Up to 283.8 Billion Won Over Five Years

Lee O-sook and 26 other members of the Jeonnam-Gwangju Special Metropolitan City council introduced an ordinance to pay all or part of uninsured obesity drug costs for residents of at least a year who have an obesity diagnosis, and low-income and young residents could get priority, Seoul Economic Daily reported. The cost estimate runs from 56.76 billion to 283.8 billion won for 2027 to 2031. Critics said the bill sets no severity criteria, and it would need Health Ministry consultation even if passed.

Novo Nordisk Relaunches NovoCare as a Free Wegovy Membership With an App, Home Delivery, and Partner Offers

Novo said the revamped NovoCare website and app combine coverage information, prescription fills, and free home delivery, which it said will soon reach eligible members with commercial or government insurance, including Medicare Bridge. Members can browse partners such as Stitch Fix, Factor, Berry Street, and WHOOP, whose costs and eligibility vary, and Novo plans a NovoCare Points rewards program by year-end.

Ascletis Files a U.S. IND for a Weekly Oral Tablet Combining an Amylin Peptide and a GLP-1/GIP/Glucagon Peptide

Hong Kong-listed Ascletis asked the FDA to begin human testing of ASC36_37o, a tablet pairing its amylin receptor agonist ASC36 with its triple agonist ASC37. In monkeys, the company reported half-lives of up to 200 hours and 96 hours and oral bioavailability above 10% and at least 9.1%. In obese rats, the combination produced about 69% more weight loss than ASC37 alone. A U.S. Phase 1 study of the amylin pill on its own is underway.